Bryan, Garnier and Co advised Santen Pharmaceutical Co. Ltd. on its successful takeover of Novagali Pharma S.A.
Share the transaction
Paris – December, 21st, 2011 – Bryan, Garnier and Co, the independent pan-European investment bank focused on growth companies, today announces it has advised Santen Pharmaceutical Co. Ltd. on its successful takeover of Novagali Pharma S.A.
Santen Pharmaceutical Co. Ltd. which had acquired in October 2011 a 50.55% controlling interest of the share capital of Novagali successfully purchased over the course of the Offer, 7,545,247 shares, 700 warrants dated 2014 and 5,406 warrants dated 2019 . Bryan, Garnier & Co acted as Broker and Sollicitation Agent on behalf of Santen Pharmaceutical Co. Ltd.
Taking into account the shares held prior to the opening of the Offer, Santen now holds directly:
– 15,788,594 shares representing 96.73% of the share capital and of the voting rights of Novagali ,
– 700 warrants dated 2014, representing 100% of the outstanding 2014 BSAs, and
– 5,406 warrants dated 2019, representing 100% of the outstanding 2019 BSAs.
Following the Offer period, the shares not held by Santen represented less than 5% of Novagali’s share capital or voting rights when excluding Novagali’s treasury shares. Thus, Santen requested from the AMF, the implementation of a squeeze-out procedure for the Novagali shares not tendered into the Offer.
For more information, please contact:
Christian Finan – Director – Equity Capital Markets / +33 (0)1 56 68 75 30 / cfinan@bryangarnier.com
About Santen Pharmaceutical Co. Ltd.
Founded in 1890, Santen is a $1 billion global company headquartered in Osaka, Japan. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe, and Asia, including its Emeryville, California based Santen Inc., its Tampere, Finland based Santen OY, its Suzhou, China based Santen Pharmaceutical (China) Co., Ltd. and its Bangalore, India based Santen India Private Limited.
For more information, visit www.santen.com.
About NOVAGALI Pharma SA
Founded in 2000, Novagali Pharma SA is a pharmaceutical company that develops and commercializes ophthalmic innovative products for all segments of the eye. Thanks to its three proprietary technology platforms, the Company has an advanced portfolio of highly innovative products, one of which is already on sale and two of which have ongoing undergoing phase III clinical trial programs. Since July 2010 Novagali Pharma has been listed on NYSE Euronext Paris – Compartment C.